Steve Broadbent - What is a reasonably likely surrogate? What is its use in PKD drug development?

C-Path Special Operations Adviser, Steve Broadbent, MBA, explains what a reasonably likely surrogate is and how it is used to help develop therapies for Polycystic Kidney Disease.

Subscribe to C-Path Now ►►

FOLLOW C-PATH:
LinkedIn:
Facebook:
Twitter:

ABOUT C-PATH:
Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path’s mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established numerous global consortia that currently include more than 1,600 scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and dozens of pharmaceutical and biotech companies. C-Path US is headquartered in Tucson, Arizona and C-Path, Ltd. EU is headquartered in Dublin, Ireland, with additional staff in multiple other locations. For more information, visit c-path.org and c-path.eu.

#CPath #drugdevelopment #clinicaltrials #PKD #PolycysticKidneyDisease #EndPoints #biomarkers #SurrogateBiomarkers #FDA #EMA

development?